Skip to main content
Year archive

Lineage Cell Therapeutics Inc. — 2023 filings

All 121 regulatory filings released by Lineage Cell Therapeutics Inc. (LCTX) in 2023, sourced directly from the official regulator.

121 Filings
2023 Period
2023 filings (121)
Filing Released Lang
Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury
Regulatory Filings
2023-12-18 English
Lineage Announces Submission of OPC1 Investigational New Drug Amendment for Treatment of Chronic and Subacute Spinal Cord Injury
Regulatory Filings
2023-12-18 English
Registration Statement on Form S-8
Capital/Financing Update
2023-11-14 English
Registration Statement on Form S-8
Share Issue/Capital Change
2023-11-14 English
Regulatory Filings 2023
Regulatory Filings
2023-11-13 English
8K-Financial results for the quarter ended September 30, 2023
Earnings Release Q3 2023
2023-11-12 English
8K-Financial results for the quarter ended September 30, 2023
Earnings Release Q3 2023
2023-11-12 English
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Earnings Release Q3 2023
2023-11-12 English
Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
Earnings Release Q3 2023
2023-11-12 English
The company's financial results for Third quarter 2023 reported abroad
Regulatory Filings
2023-11-12 Hebrew (modern)
Interim / Quarterly Report 2023
Interim / Quarterly Report Q3 2023
2023-11-09 English
Regulatory Filings 2023
Regulatory Filings
2023-11-09 English
Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023.
Earnings Release Q3 2023
2023-11-01 English
Cell Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on November 9, 2023.
Report Publication Announcement
2023-11-01 English
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting
Regulatory Filings
2023-10-24 English
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at Eyecelerator at 2023 American Academy of Ophthalmology (AAO) Annual Meeting
Report Publication Announcement
2023-10-24 English
Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells
Regulatory Filings
2023-10-16 English
Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells
Report Publication Announcement
2023-10-16 English
RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Earnings Release Q4 2023
2023-10-16 English
RG6501 (OpRegen®) Phase 1/2a Results Show Evidence of Rapid Improvement of Outer Retinal Structure in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Report Publication Announcement
2023-10-16 English
Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023
Report Publication Announcement
2023-09-19 English
Lineage to Present at Cantor Fitzgerald 2023 Global Healthcare Conference on September 27, 2023
Regulatory Filings
2023-09-19 English
RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress
Earnings Release Q3 2023
2023-09-14 English
RG6501 (OpRegen®) Phase 1/2a Additional Results to Be Featured at 23rd EURETINA Congress
Report Publication Announcement
2023-09-14 English
Lineage to Present at 2023 International Spinal Research Trust Network Meeting
Regulatory Filings
2023-09-12 English
Lineage to Present at 2023 International Spinal Research Trust Network Meeting
Report Publication Announcement
2023-09-12 English
Results of Annual Meeting was held on September 6, 2023
AGM Information
2023-09-10 English
Results of Annual Meeting was held on September 6, 2023
Report Publication Announcement
2023-09-10 English
Regulatory Filings 2023
Regulatory Filings
2023-09-07 English
Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics.
Regulatory Filings
2023-09-06 English
Initiation of Development Activities for Hypoimmune Pluripotent Cell Line for Neurology Indications Under Partnership With Eterna Therapeutics.
Report Publication Announcement
2023-09-06 English
LINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Earnings Release Q2 2023
2023-08-13 English
LINEAGE CELL THERAPEUTICS REPORTS SECOND QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
Report Publication Announcement
2023-08-13 English
Form 10-Q For the quarterly period ended June 30, 2023
Interim / Quarterly Report H1 2023
2023-08-13 English
Form 10-Q For the quarterly period ended June 30, 2023
Report Publication Announcement Q2 2023
2023-08-13 English
The company's financial results for the second quarter 2023 were published abroad
Report Publication Announcement
2023-08-13 Hebrew (modern)
Interim / Quarterly Report 2023
Interim / Quarterly Report Q2 2023
2023-08-10 English
Regulatory Filings 2023
Regulatory Filings
2023-08-10 English
Important notice regarding the availability of proxy materials for the shareholders meeting to be held on September 6, 2023 for shareholders of record as of July 20, 2023
Proxy Solicitation & Information Statement
2023-08-02 English
Important notice regarding the availability of proxy materials for the shareholders meeting to be held on September 6, 2023 for shareholders of record as of July 20, 2023
Report Publication Announcement
2023-08-02 English
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held September 6, 2023
Proxy Solicitation & Information Statement
2023-08-02 English
NOTICE OF ANNUAL MEETING OF SHAREHOLDERS To Be Held September 6, 2023
Proxy Solicitation & Information Statement
2023-08-02 English
Annual Report 2023
Annual Report
2023-07-27 English
Regulatory Filings 2023
Regulatory Filings
2023-07-27 English
Proxy Solicitation & Information Statement 2023
Proxy Solicitation & Information Statement
2023-07-27 English
Regulatory Filings 2023
Regulatory Filings
2023-07-11 English
Director's Dealing 2023
Director's Dealing
2023-07-03 English
Director's Dealing 2023
Director's Dealing
2023-07-03 English
Director's Dealing 2023
Director's Dealing
2023-07-03 English
Director's Dealing 2023
Director's Dealing
2023-07-03 English
Director's Dealing 2023
Director's Dealing
2023-07-03 English
Director's Dealing 2023
Director's Dealing
2023-07-03 English
Director's Dealing 2023
Director's Dealing
2023-07-03 English
Director's Dealing 2023
Director's Dealing
2023-07-03 English
NOTICE OF 2023 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD SEPTEMBER 6, 2023
AGM Information
2023-06-22 English
NOTICE OF 2023 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD SEPTEMBER 6, 2023
AGM Information
2023-06-22 English
Regulatory Filings 2023
Regulatory Filings
2023-06-21 English
Expected to Be Added to Russell 3000® Index
Regulatory Filings
2023-05-22 English
Expected to Be Added to Russell 3000® Index
Regulatory Filings
2023-05-22 English
PROSPECTUS SUPPLEMENT Up to $63,857,188 Common Shares
Capital/Financing Update
2023-05-21 English
PROSPECTUS SUPPLEMENT Up to $63,857,188 Common Shares
Regulatory Filings
2023-05-21 English
Opinion of Sheppard, Mullin, Richter & Hampton LLP, dated May 18, 2023, with respect to the legality of certain common shares being issued
Regulatory Filings
2023-05-21 English
Opinion of Sheppard, Mullin, Richter & Hampton LLP, dated May 18, 2023, with respect to the legality of certain common shares being issued
Report Publication Announcement
2023-05-21 English
Regulatory Filings 2023
Regulatory Filings
2023-05-18 English
Regulatory Filings 2023
Regulatory Filings
2023-05-18 English
Form 10-Q-REPORTS FIRST QUARTER 2023
Interim / Quarterly Report Q1 2023
2023-05-12 English
Form 10-Q-REPORTS FIRST QUARTER 2023
Report Publication Announcement
2023-05-12 English
8k- REPORTS FIRST QUARTER 2023
Earnings Release Q1 2023
2023-05-12 English
8k- REPORTS FIRST QUARTER 2023
Report Publication Announcement
2023-05-12 English
Interim / Quarterly Report 2023
Interim / Quarterly Report Q1 2023
2023-05-11 English
Regulatory Filings 2023
Regulatory Filings
2023-05-11 English
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM).
Regulatory Filings
2023-05-09 English
Lineage Receives Grant From California Institute for Regenerative Medicine (CIRM).
Report Publication Announcement
2023-05-09 English
Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
Earnings Release Q1 2023
2023-05-04 English
Lineage Cell Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023
Report Publication Announcement
2023-05-04 English
Annual Report 2022
Annual Report FY 2022
2023-04-27 English
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
Earnings Release Q2 2023
2023-04-27 English
RG6501 (OpRegen®) Phase 1/2a Clinical Results Support the Potential for OpRegen to Slow, Stop or Reverse Disease Progression in Geographic Atrophy Secondary to Age-Related Macular Degeneration
Report Publication Announcement
2023-04-27 English
Lineage to Present at 2023 AAPS National Biotechnology Conference.
Regulatory Filings
2023-04-18 English
Lineage to Present at 2023 AAPS National Biotechnology Conference.
Report Publication Announcement
2023-04-18 English
Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium
Legal Proceedings Report
2023-03-30 English
Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium
Report Publication Announcement
2023-03-30 English
Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium
Regulatory Filings
2023-03-30 English
Lineage and the Christopher & Dana Reeve Foundation Proudly Present the 1st Annual Spinal Cord Injury Investor Symposium
Report Publication Announcement
2023-03-30 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2023-03-12 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Major Shareholding Notification
2023-03-12 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2023-03-12 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2023-03-12 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2023-03-12 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
Director's Dealing
2023-03-12 English
FORM 10K- For the fiscal year ended December 31, 2022
Annual Report FY 2022
2023-03-11 English
FORM 10K- For the fiscal year ended December 31, 2022
Report Publication Announcement
2023-03-11 English
Form 8K - Lineage Cell Therapeutics reports fourth quarter and full year 2022 financial results and provides business update
Earnings Release FY 2022
2023-03-11 English
Form 8K - Lineage Cell Therapeutics reports fourth quarter and full year 2022 financial results and provides business update
Report Publication Announcement
2023-03-11 English
Director's Dealing 2023
Director's Dealing
2023-03-11 English
Director's Dealing 2023
Director's Dealing
2023-03-11 English
Director's Dealing 2023
Director's Dealing
2023-03-11 English
Director's Dealing 2023
Director's Dealing
2023-03-11 English
Annual Report 2022
Annual Report FY 2022
2023-03-09 English
Regulatory Filings 2023
Regulatory Filings
2023-03-09 English
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D
Report Publication Announcement
2023-03-06 English
RG6501 (OpRegen®) Phase 1/2a Results to Be Featured at 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Presentation by Eyal Banin, M.D., Ph.D
Report Publication Announcement
2023-03-06 English
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023, Conference call and webcast on March 9, 2023, at 4:30 p.m. Eastern
Earnings Release Q4 2022
2023-03-02 English
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on March 9, 2023, Conference call and webcast on March 9, 2023, at 4:30 p.m. Eastern
Report Publication Announcement
2023-03-02 English
Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
Regulatory Filings
2023-02-22 English
Lineage Enters Into Option and License Agreement With Eterna Therapeutics to Develop Hypoimmune Pluripotent Cell Lines for Multiple Neurology Indications
Report Publication Announcement
2023-02-22 English
Form 4 - Statement of Changes in Beneficial Ownership - Samuel George A. III
Director's Dealing
2023-02-15 English
Form 4 - Statement of Changes in Beneficial Ownership - Samuel George A. III
Director's Dealing
2023-02-15 English
Form 4 - Statement of Changes in Beneficial Ownership - Hogge Gary S.
Director's Dealing
2023-02-15 English
Form 4 - Statement of Changes in Beneficial Ownership - Hogge Gary S.
Director's Dealing
2023-02-15 English
Form 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP - Culley Brian M
Director's Dealing
2023-02-15 English
Form 4 - STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP - Culley Brian M
Director's Dealing
2023-02-15 English
FORM 5 - ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- KINGSLEY ALFRED
Director's Dealing
2023-02-15 English
FORM 5 - ANNUAL STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES- KINGSLEY ALFRED
Major Shareholding Notification
2023-02-15 English
Director's Dealing 2023
Director's Dealing
2023-02-14 English
Director's Dealing 2023
Director's Dealing
2023-02-14 English
Director's Dealing 2023
Director's Dealing
2023-02-14 English
Director's Dealing 2023
Director's Dealing
2023-02-14 English
8K- Corporate Presentation - January 2023
Investor Presentation
2023-01-24 English
8K- Corporate Presentation - January 2023
Investor Presentation
2023-01-24 English
Regulatory Filings 2023
Regulatory Filings
2023-01-23 English